Merck says no safety concerns observed in molnupiravir phase-3 trial, shared relevant data with DCGI, Health News, ET HealthWorld
Merck Sharp & Dohme (MSD) on Friday said its COVID antiviral molnupiravir has cut the risk of hospitalization or death in Phase 3 clinical trial with no observed safety concerns…
